New Fleet Maintenance Software Integration from EROAD & Fleetpal Boosts Fleet Efficiency
SAN DIEGO, July 8, 2025 /PRNewswire/ — EROAD, a global leader in connected fleet management solutions, today announced a strategic partnership with Fleetpal, a fast-growing provider of commercial vehicle maintenance management software.
Together, the companies are delivering an integrated, digitized experience for fleets, making it easier than ever for carriers to streamline maintenance, strengthen compliance, and optimize performance.
With this partnership, EROAD's comprehensive telematics and fleet management platform seamlessly connects with Fleetpal's robust maintenance tracking platform.
The combination of EROAD and Fleetpal's solutions empowers fleets to:
automatically trigger maintenance schedules based on accurate telematics,
streamline repair and service workflows, and
ensure all compliance records are digital and audit ready.
With essential data accessible in one easy-to-use interface, customers will experience reduced downtime, fewer unexpected breakdowns, lower maintenance costs, and greater confidence in meeting regulatory requirements. Without this integration, fleets face ongoing challenges such as manual entry of vehicle and odometer data, lost visibility into defects and inspection issues, outdated maintenance scheduling, and communication breakdowns between drivers, technicians, and fleet managers.
Fleetpal delivers a modern, cloud-based maintenance solution designed for fast adoption by EROAD customers. With an intuitive interface and streamlined onboarding, users can get up and running quickly, enabling immediate time and cost savings. Fleetpal's open APIs allow for seamless integration with the EROAD platform, giving customers the flexibility to combine EROAD's trusted telematics with Fleetpal's powerful, easy-to-use maintenance tools.
'This partnership with Fleetpal marks a significant advancement in North American fleet management. By integrating our telematics data with Fleetpal's maintenance platform, we're delivering a truly unified solution that streamlines workflows, reduces downtime, and lowers costs for our customers,' said Robert L. Tri, SVP Sales at EROAD. 'This is a game-changer for fleet operators seeking to maximize efficiency and improve their bottom line.'
'Fleetpal is dedicated to making fleet maintenance simple, transparent, and effective,' added Mike Valnev, CEO of Fleetpal. 'Integrating with EROAD ensures our customers have access to the highest quality data and insights for smarter maintenance decisions. Together, we are helping carriers drive operational excellence and remain focused on safety and compliance, all while running a profitable business.'
The EROAD and Fleetpal integration is available immediately. Existing and new customers can contact either company to learn more about the enhanced features and benefits.
About EROAD
EROAD aims to help customers grow by providing innovative solutions that offer a deep and comprehensive range of highly contextualized data across driver, asset, and load performance. Our solutions deliver robust visibility into critical issues and translate this data into actionable insights, enabling customers to improve their operations. EROAD's hardware and connectivity solutions set the industry standard for accuracy and reliability, significantly enhancing the efficiency and productivity of fleet operations across the transportation, cold chain, and construction segments.
Our unwavering commitment remains focused on creating safer and more sustainable roads for all. EROAD (ERD) is dual listed on the ASX and NZX and boasts a team of more than 400 professionals located across New Zealand, Australia, Manila, and North America.
About Fleetpal
Fleetpal is a Fleet Maintenance Management Software (FMMS) SaaS company on a mission to make fleet maintenance smarter, simpler, and more cost-effective. Our platform empowers fleet operators with the tools and insights they need to make smarter, data-driven decisions—ensuring vehicles stay on the road and businesses stay ahead.
Fleetpal empowers maintenance teams to spend the right amount, at the right time, on the right repairs—helping fleets maximize uptime, maintain compliance, and be more proactive. Our platform consolidates maintenance data into a single, actionable view, giving our partners the clarity and control needed to optimize every dollar spent and every mile driven.
Fleetpal serves as a centralized hub for maintenance data, giving fleet managers the clarity and control they need to track performance, anticipate issues, and plan proactively. From preventative maintenance scheduling to repair tracking and cost analysis, we enable all stakeholders to work together more effectively—reducing downtime, streamlining workflows, and ensuring that every maintenance decision supports long-term operational success.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 hours ago
- Malaysian Reserve
U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer
Orphan drug designation highlights the potential for ADRX-0405 to address the high unmet need in gastric cancer SAN DIEGO, July 8, 2025 /PRNewswire/ — Adcentrx Therapeutics ('Adcentrx'), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ADRX-0405, for the treatment of patients with gastric cancer. ADRX-0405 is a STEAP1 ADC being evaluated in the Phase 1a portion of an ongoing Phase 1a/b clinical trial (NCT06710379) for the treatment of select advanced solid tumors, including metastatic castration resistant prostate cancer, gastric cancer, and non-small cell lung cancer. While STEAP1 is primarily associated with prostate cancer, there is a meaningful amount of target expression in gastric cancer, making this a potential indication of interest for future clinical development. 'Receiving orphan drug designation from FDA is a notable milestone for Adcentrx and reinforces the potential for ADRX-0405 to improve the lives of patients with gastric cancer,' said Hui Li, Ph.D., Founder and Chief Executive Officer of Adcentrx. 'We are encouraged by the progress of our Phase 1a trial and look forward to further evaluating the safety, tolerability and anti-tumor activity of ADRX-0405 in gastric and other cancers.' Gastric cancer, or stomach cancer, is a serious malignancy that develops in the stomach lining and is often diagnosed at advanced stages. The American Cancer Society estimates there will be 30,300 new cases of gastric cancer in the U.S. in 2025, meeting FDA's criteria for a rare disease. The orphan drug designation is a program designed to stimulate the development of treatments for rare diseases, defined as conditions affecting fewer than 200,000 people in the U.S. Benefits of this designation include access to grant funding and scientific assistance, tax credits for qualified clinical trials, waiver of Prescription Drug User Fee Act (PDUFA) application fees, and the potential for seven years of market exclusivity following regulatory approval. About ADRX-0405ADRX-0405 is a clinical-stage next-generation ADC targeting six-transmembrane epithelial antigen of the prostate 1 (STEAP1), a cell surface protein that is upregulated in prostate cancer and certain other cancers with limited expression in normal healthy tissue. The ADC is composed of a humanized IgG1 antibody coupled with a novel topoisomerase inhibitor linker-payload through Adcentrx's innovative i-Conjugation® technology platform – a core component in the design of the company's ADCs. The platform utilizes a cleavable linker and stable conjugation chemistry to enhance payload delivery. This novel technology enables a highly stable ADC with a drug-antibody ratio of eight (DAR 8) to maximize payload delivery to solid tumors. ADRX-0405 preclinical studies have demonstrated its favorable pharmacokinetics, safety profile, and significant efficacy across multiple animal tumor models. ADRX-0405 is currently being evaluated in a Phase 1a/b clinical trial. For more information about the ADRX-0405 Phase 1a/b clinical trial, please refer to the Study ID NCT06710379 on About Adcentrx TherapeuticsAdcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. Adcentrx has pioneered the development of an ADC technology platform addressing key components of protein conjugate design to solve challenges typically seen in ADCs. Adcentrx is developing a robust pipeline including two clinical-stage ADCs and multiple preclinical ADCs, all with first-in-class and best-in-class potential. For more information about Adcentrx and its innovative ADC technologies, please visit Contact Information:Investor Relationsir@
Malaysian Reserve
4 hours ago
- Malaysian Reserve
Green Coffee Company and Los Angeles Rams Announce New Multi-Year Partnership to Make Juan Valdez® the Official Coffee of the Rams
MIAMI, July 8, 2025 /PRNewswire/ — Today, Green Coffee Company and the Los Angeles Rams announced a multi-year partnership to make the iconic Juan Valdez® coffee, produced by GCC in the USA, the Official Coffee of the Los Angeles Rams. With this exciting partnership, fans attending Rams home games will be able to enjoy Juan Valdez® 100% premium Colombian coffee—served both hot and as cold brew—throughout the stadium, starting this season. Through this collaboration, which highlights the shared commitment between the Colombian coffee company and GCC to sustainability and innovation, Juan Valdez will expand its presence in the competitive North American market and have the opportunity to connect with a diverse and discerning audience through high-quality coffee and an experience that celebrates Colombian culture. 'Premium 100% Colombian coffee is coming to captivate Rams fans. This announcement is an important milestone in our mission to bring the best of Juan Valdez to the North American market, highlighting the brand's commitment to sustainability and innovation,' said Ted Skodol, Chief Revenue Officer of Green Coffee Company, the company supporting the distribution of Juan Valdez roasted coffee and coffee beverages across supermarkets and institutional channels. The executive also said, 'Through this partnership with the Los Angeles Rams, we are opening a new chapter in the brand's global presence, bringing its authenticity and quality to an even broader audience.' 'Being part of a team like the Los Angeles Rams is a powerful example of how far Colombian coffee can go when there is passion, purpose, and global vision behind it. Thanks to our alliance with Green Coffee Company—allowing us to elevate the presence of the more than 550,000 coffee-growing families who cultivate, with dedication and pride, a product of exceptional quality,' commented Sebastian Mejia, General Manager, Juan Valdez North America. He also added that 'being present in such an iconic scenario as this, allows us to connect with global consumers, share our culture and continue consolidating Colombia as a reference of coffee excellence at an international level.' As part of this exclusive partnership, a special edition of Juan Valdez® x Rams coffee will be created, along with various activations featuring player images and a prominent advertising presence throughout the stadium. Additionally, digital content series 'Recreate an Old Photo' and content from Media Day will be developed and shared across the team's official social media channels. 'The Los Angeles Rams and Juan Valdez® Colombian Coffee are united by a shared commitment to excellence and inspiring communities, making this partnership a natural fit,' said Jennifer Prince, Chief Commercial Officer, Los Angeles Rams. This collaboration creates a strategic platform for bringing the flavor of premium Colombian coffee to the American sports experience.
Malaysian Reserve
6 hours ago
- Malaysian Reserve
CENTERSPACE ANNOUNCES SECOND QUARTER 2025 EARNINGS RELEASE DATE
MINNEAPOLIS, July 8, 2025 /PRNewswire/ — Centerspace (NYSE: CSR) will release its operating results for the quarter ended June 30, 2025, after the market closes on Monday, August 4, 2025. Management will host a conference call to discuss those results on Tuesday, August 5, 2025, at 10:00 a.m. Eastern Time. Interested parties may access the conference call via the following: Live Conference Call Details: Live webcast: Operator Assisted Dial-In:United States (Local): +1 404 975 4839United States (Toll-Free): +1 833 470 1428Canada: +1 226 828 7575Canada (Toll-Free): +1 833 950 0062Access Code: 547256 Replay Details: Replay Expiration Date: Tuesday, August 12, 2025 11:59 PM EDT Replay Dial-In:United States (Local): +1 929 458 6194United States (Toll-Free): +1 866 813 9403Access Code: 134183 About Centerspace Centerspace is an owner and operator of apartment communities committed to providing great homes by focusing on integrity and serving others. Founded in 1970, the company currently owns 72 apartment communities consisting of 13,353 homes located in Colorado, Minnesota, Montana, Nebraska, North Dakota, South Dakota, and Utah. Centerspace was named a top workplace for the sixth consecutive year in 2025 by the Minneapolis Star Tribune. For more information, please visit If you would like more information about this topic, please contact Josh Klaetsch, Investor Relations, at (952) 401-6600 or IR@ Contact Information Josh Klaetsch, Investor Relations Phone : (952) 401-6600 E-mail : IR@
